placebo for one post-medication time point and one readout variable that are most likely to be significant based on published literature (see power calculation).
← all excerpts
IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET).
1
—
—